Efekat butilftalida u kombinaciji sa citikolinom na neurotrofne faktore i oksidativni stres posle cerebralnog infarkta
Sažetak
Background: To compare the effects of butylphthalide (BP) combined with citicoline (COPC) or vascular rehabilitation capsules (VRC), respectively, on vascular dementia (VD) after cerebral infarction (CI).
Methods: 98 patients with VD after CI who were seen in our hospital from April 2020 to June 2022 were selected as the study population. Among them, 52 patients received BP combined with COPC (BP+COPC group), while the rest 46 received BP combined with VRC (BP+VRC group). Fasting venous blood was drawn from the patients before and after treatment, respectively, and the levels of nerve growth factor (NGF), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF), superoxide dismutase (SOD), malondialdehyde (MDA), Tumor necrosis factor-α (TNF-α), Interleukin-1β (IL-1β), and C-reactive protein (CRP) were measured. Cognitive and neurological improvements were assessed using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) and the National Institute of Health stroke scale (NIHSS). In addition, the patient's cerebral hemodynamics were examined by CT.
Results: After treatment, LOTCA increased in both groups and were higher in BP+COPC group than in BP+VRC group (P<0.05), while NIHSS decreased in BP+COPC group than in BP+VRC group (P<0.05). NSE, MDA, IL-1β, CRP, and TNF-α decreased in both groups after treatment, while NGF, BDNF, and SOD increased, again with more significant changes in BP+COPC group (P<0.05). In addition, cerebral hemodynamics was more favorable in BP+COPC group than in BP+VRC group (P<0.05) .
Conclusion: BP combined with COPC has superior improvement in neurologic function in patients with VD after CI.
Sva prava zadržana (c) 2025 Zhongjun Chen, Dongyun Wu, Jiajun Pan, Xinhong Fan
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.